Low-Dose vs. Standard-Dose Nintedanib at Initiation in Fibrosing ILD: A Target-Trial Emulation of Treatment Persistence and Lung Function - PubMed
6 hours ago
- #Nintedanib
- #Interstitial Lung Disease
- #Treatment Persistence
- Study compares low-dose (100 mg) vs. standard-dose (150 mg) nintedanib initiation in fibrosing ILD.
- Low-dose initiation extended 12-month treatment persistence by 52.9 days and reduced discontinuation risk.
- Lung function (FVC %predicted) changes were broadly similar between doses but with imprecise estimates.
- Findings suggest a 'start-low, escalate-as-tolerated' policy may improve treatment persistence without compromising lung function.
- Prospective evaluation of dose escalation strategies is warranted.